Locations:
Search IconSearch

How Are You Shortening Kids’ Infusion Visits?

The short answer from Rabi Hanna, MD

650×450-Pediatric-Chemo-Infusion

Q: How are you shortening kids’ infusion visits?

A: When our young patients come for infusion, they often bring family with them. Patients will see their physician first and then get chemotherapy. We noticed that patients and their guests were waiting too long between provider visit and infusion. The average wait time was one hour and 45 minutes.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Our department set a goal to decrease that time by 20 percent. But I’m excited to say that we decreased it by 69 percent — to just 33 minutes! That’s more than one hour per visit that patients can save here and spend with family and friends at home or school instead.

A couple of changes led to this time savings. First, we cleared up a lag in communication between physicians and the infusion team. We introduced a more streamlined way for physicians to release orders when a patient was ready for treatment. This alone reduced average wait time from 105 minutes to 79 minutes.

Second, we moved patients’ lab visits before rather than after seeing their physician. That enabled physicians to write an order during the office visit, clearing the patient for infusion sooner — taking another 46 minutes off wait time.

In addition to shortening time to treatment, these changes also have improved the predictability of treatment time. Our standard deviation used to be 59 minutes. Now it’s 33 minutes. We can say with more certainty when the patient will begin and finish their infusion, which not only benefits the patient but also better directs our staffing.

The best part about these solutions is that they came from our front-line caregivers.

We convened a six-member team with a physician, nurse practitioner, nurse, pharmacist, front desk caregiver and quality management caregiver. Each went through our kaizen continuous improvement process, including doing a root-cause analysis of our wait times. Some walked in the footsteps of patients going to infusion. All talked with their colleagues about what was or wasn’t working and collected recommendations for improvement.

Advertisement

Evaluating the situation and then developing and implementing changes took six weeks. Because we involved everyone in the process, the changes will be more sustainable. Now more than a month later we’re seeing the same wonderful results.

Rabi Hanna, MD
Chairman, Pediatric Hematology-Oncology and Bone Marrow Transplant

Advertisement

Related Articles

Dr. Barry examining a patient

When Standard Scopes Are Not Enough: Advanced Endoscopy in Pediatric GI Care

Minimally invasive options for conditions that may otherwise require surgery or referral to adult centers

Dr. Amdani examines a young patient
April 7, 2026/Pediatrics/Cardiology

How to Evaluate and Manage Children With Acute Decompensated Heart Failure

AHA statement provides the latest comprehensive, evidence-based information

Dr. Sharma speaks with colleague in the lab

Cleveland Clinic Launches National Tumor Board for DNA Repair and Telomere Biology Disorders

Helping clinicians manage cancer treatment in patients with complex biology

Baby with torticollis lies on back

Breech Positioning Is the Only Intrauterine Constraint Factor Linked to Torticollis Severity, Study Finds

Infants with > 30° of cervical tightness were also more likely to be younger at evaluation

boy receiving nasal swap for covid test

SARS-CoV-2 Influenced Other Viruses in Different Ways

Findings hold lessons for future pandemics

Dr. Weaver smiling with a pediatric patient
February 6, 2026/Pediatrics/Urology

Rethinking the Diagnostic Paradigm for Pediatric Kidney Abnormalities

One pediatric urologist’s quest to improve the status quo

MRI images of pediatric kidney disease
February 3, 2026/Pediatrics/Nephrology

Developing Imaging Biomarkers for Autosomal Recessive Polycystic Kidney Disease

Overcoming barriers to implementing clinical trials

gene editing

Novel Gene Editing Therapy for Sickle Cell Disease Continues to Free Patients From Severe Vaso-Occlusive Pain

Interim results of RUBY study also indicate improved physical function and quality of life

Ad